Results 291 to 300 of about 364,595 (399)

Good Medicine: Why Pharmacists Should Be Prescribed a Right of Conscience [PDF]

, 2010
Duffy, Michael E.
core   +2 more sources

The Literature and the Pharmacist [PDF]

Drug Intelligence & Clinical Pharmacy, 1975
openaire   +3 more sources

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

Molecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim   +11 more
wiley   +1 more source

Process evaluation of a pragmatic, multicentre pilot Randomised Controlled Trial (RCT) in primary care: Tailored intervention for COPD and Co-morbidities by Pharmacists and Consultant Physicians (TICC PCP). [PDF]

PLoS One
Wood K, Lowrie R, Smith G, Anderson D, Moir J, Attwood L, McPherson A, Sheikh A, Rankine E, Mair FS.   +9 more
europepmc   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Multicenter Renal Pharmacist Group-Pharmaceutical Care for Patients with Renal Impairment at Four Non-University Hospitals in Germany. [PDF]

J Clin Med
Seiberth S, Bayerlein K, Gerke AK, Ihbe-Heffinger A, Schobel HP, Rudolph J, Leuschner S, Müller P, Richling I, Owandner B, Schmidt-Schnaubelt T, Sieg M, Albus L, von Ameln-Mayerhofer A, Strobach D.   +14 more
europepmc   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Exploring multidimensional determinants of medication error reporting in China: a qualitative study using the theoretical domains framework. [PDF]

Front Pharmacol
Guo H, Guo Q, Wang X, Liu Y, Wang Z.
europepmc   +1 more source

Pharmacists\u27 Right of Conscience: Strategies for Showing Respect for Pharmacists\u27 Beliefs While Maintaining Adequate Care for Patients [PDF]

, 2006
Yoder, Jessica D.
core   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source